Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Januar 2023

Genmab — Januar 2023

Planlagt Fastgjort Låst Flyttet Genmab
644 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • R Offline
    R Offline
    Riis7
    wrote on sidst redigeret af
    #575

    Men det er u

    1 Reply Last reply
    0
    • R Offline
      R Offline
      Riis7
      wrote on sidst redigeret af
      #576

      Umuligt og ramme bund og top i Genmab 😉 så nok godt tidpunkt som du skriver hvis man tænker langsigtede:-)

      1 Reply Last reply
      0
      • S Offline
        S Offline
        Sukkeralf
        wrote on sidst redigeret af
        #577

        https://endpts.com/jj-quietly-punts-a-pair-of-early-stage-bispecifics-for-solid-tumors/

        1 Reply Last reply
        0
        • S Offline
          S Offline
          Sukkeralf
          wrote on sidst redigeret af
          #578

          Just a moment...

          favicon

          (www.fiercebiotech.com)

          1 Reply Last reply
          0
          • R Offline
            R Offline
            Riis7
            wrote on sidst redigeret af
            #579

            Det virker til folk sælger ud af Pharma og over i tech i 2023

            1 Reply Last reply
            0
            • S Offline
              S Offline
              Sukkeralf
              wrote on sidst redigeret af
              #580

              The other culled project, JNJ-8902, focused specifically on prostate cancer, with a phase 1 study looking to enroll more than twice as many patients as the JNJ-6358 trial. Recruitment wrapped up in September, and few updates have been posted since, except a pushback of the expected completion date from January 2023 to the end of June 2023. The trial was similarly not recruiting out of the U.S. but did include trial sites in Canada in addition to Israel and Spain.

              1 Reply Last reply
              0
              • S Offline
                S Offline
                Sukkeralf
                wrote on sidst redigeret af
                #581

                JNJ-902 var vel et DuoBody BsAb

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #582

                  yes it was. it isn't a surprise as they stopped recruiting in september. it isn't completely dead, the trial continues with existing patients but i don't think we should expect anything anymore on it.

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #583

                    then again, i don't think you did if i remember correctly
                    😉

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #584

                      JNJ's pipeline priorities https://jnj-content-lab.brightspotcdn.com/18/f6/b12412444e76b6f9775371de1dd0/jnj-pipeline-4q2022.pdf

                      1 Reply Last reply
                      0
                      • S Offline
                        S Offline
                        Sukkeralf
                        wrote on sidst redigeret af
                        #585

                        No I remember we talked about this asset before so thats was kind of expected

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #586

                          another small Teclistamab in Combination with Daratumumab trial https://clinicaltrials.gov/ct2/show/NCT05695508

                          1 Reply Last reply
                          0
                          • P Offline
                            P Offline
                            ProinvestorNEWS
                            wrote on sidst redigeret af
                            #587

                            Regnskabssæsonen - kontant afregning ved kasse 1
                            Regnskabssæsonen er for alvor i gang. Goldman Sachs, Tesla, Topdanmark, Tryg og Netcompany er oppe at vende. Derudover kommer Helge Larsen ind på pharma-, biotek- og laksesektoren.

                            Kort video: https://www.proinvestor.com/boards/109855

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #588

                              EPCORE DLBCL-2
                              started recruiting earlier this month https://clinicaltrials.gov/ct2/show/NCT05578976

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #589

                                Study Shows Activity of Talquetamab in Highly Refractory Multiple Myeloma https://ascopost.com/issues/january-25-2023/study-shows-activity-of-talquetamab-in-highly-refractory-multiple-myeloma/

                                1 Reply Last reply
                                0
                                • B Offline
                                  B Offline
                                  bikube
                                  wrote on sidst redigeret af
                                  #590

                                  Jeg lod mig narre af "EPCORE_DLBCL 2". Det er fase 3.

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #591

                                    and EPCORE DLBCL-3 is phase 2, just to make it easy for you 😉

                                    1 Reply Last reply
                                    0
                                    • B Offline
                                      B Offline
                                      bikube
                                      wrote on sidst redigeret af
                                      #592

                                      HaHa.

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #593

                                        Case report: Relapsed/refractory extranodal natural killer/T-cell lymphoma nasal type with extensive central nervous system involvement https://pubmed.ncbi.nlm.nih.gov/36699620/ "We add to existing limited data that Daratumumab penetrates the blood-brain barrier."

                                        1 Reply Last reply
                                        0
                                        • SolsenS Offline
                                          SolsenS Offline
                                          Solsen
                                          wrote on sidst redigeret af
                                          #594

                                          Det bliver interessante data med Carvykti https://www.businesswire.com/news/home/20230127005056/en/Legend-Biotech-Announces-Phase-3-CARTITUDE-4-Study-of-CARVYKTI®-ciltacabtagene-autoleucel-Has-Met-Its-Primary-Endpoint-in-the-Treatment-of-Patients-with-Relapsed-and-Refractory-Multiple-Myeloma

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper